8-K: United Health Products Announces OTCQB Uplisting and FDA Update

United Health Products announces its common shares have been uplisted to the OTCQB Venture Market and provides an update on its FDA application for CelluSTAT Hemostatic Gauze.

Summary

• United Health Products (UHP) announced its common shares have been uplisted from the OTC Pink market to the OTCQB Venture Market, effective May 1, 2025.
• The company believes this uplisting will increase visibility and liquidity as it progresses with its FDA Premarket Approval application for CelluSTAT Hemostatic Gauze.
• The FDA notified UHP on April 25, 2025, that it declined to approve the Investigational Device Exemption (IDE) application for a follow-on clinical study.
• The FDA cited findings from Bioresearch Monitoring (BIMO) audits of the initial 2019 clinical study, to which UHP responded on October 25, 2024, and April 14, 2025.
• UHP and the FDA are scheduling a teleconference to resolve the issue and potentially allow the clinical study to proceed.
• UHP continues to advance clinical study tasks that can be completed before IDE approval.
• There is no guarantee that the FDA Premarket Approval application will be granted.
• CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding, and UHP is seeking approval to access the human surgical market.

Sentiment

Score: 5

Explanation: The news is mixed. The OTCQB uplisting is positive, but the FDA's rejection of the IDE application is a significant setback. The company is actively working to address the FDA's concerns, but the outcome is uncertain.

Positives

• The uplisting to the OTCQB Venture Market is expected to boost visibility and liquidity for UHP's stock.
• The company is actively working to resolve the FDA's concerns regarding the IDE application.
• UHP is continuing to advance clinical study tasks that can be completed before IDE approval.

Negatives

• The FDA declined to approve UHP's Investigational Device Exemption (IDE) application for a follow-on clinical study.
• The FDA cited findings from Bioresearch Monitoring (BIMO) audits of the initial 2019 clinical study.
• There is no assurance that the FDA Premarket Approval application will be granted.

Risks

• The FDA may not approve the Investigational Device Exemption (IDE) application, delaying the clinical study.
• The FDA Premarket Approval application may not be granted, preventing UHP from accessing the human surgical market.
• The company's future results are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from forward-looking statements.

Future Outlook

The company is focused on resolving the FDA's concerns regarding the IDE application and advancing its clinical study tasks. The company hopes to have a teleconference with the FDA in the next 10 days to resolve the issue.

Management Comments

• Brian Thom, UHP's Chief Executive Officer, stated that the uplisting to the OTCQB Venture Market is an important milestone for the company and reflects UHP's commitment to improving corporate transparency, increasing share trading liquidity, and expanding the universe of potential investors.

Industry Context

The OTCQB is a premier marketplace for developing companies, including those in the medical technology sector, suggesting UHP is positioning itself among similar companies seeking growth and visibility.

Comparison to Industry Standards

• The document does not contain enough information to make a comparison to industry standards.
• More information about the company's financial performance, product efficacy, and regulatory timelines would be needed to assess its position relative to competitors like Baxter International, Becton Dickinson, or Medtronic in the hemostatic gauze market.

Stakeholder Impact

• Shareholders may experience increased liquidity and visibility due to the OTCQB uplisting.
• The delay in the clinical study could impact the timeline for commercializing CelluSTAT Hemostatic Gauze.
• The FDA's decision affects the company's ability to access the human surgical market.

Next Steps

• UHP will participate in a teleconference with the FDA to address concerns regarding the IDE application.
• UHP will continue to advance clinical study tasks that can be completed prior to IDE approval.
• UHP will seek Premarket Approval from the FDA for its CelluSTAT Hemostatic Gauze.

Key Dates

Keywords

OTCQB, Uplisting, FDA, CelluSTAT, Hemostatic Gauze, United Health Products, UEEC, Premarket Approval, IDE, Clinical Study